Blog

Latest News
Managing stage 3 chronic kidney disease in primary care

Managing stage 3 chronic kidney disease in primary care

Stage 3 chronic kidney disease (CKD) is estimated to affect over 30 million adults in the United States. Patients with advanced CKD, defined for our purposes as stage 4 and 5, will often have ongoing follow ups with a nephrologist. However, in CKD stage 3 (defined as eGFR 30-59mL/min) the PCP will often be at the helm of treatment. Managing CKD stage 3 can be complex, having a clinical pharmacist meet with your CKD patients prior to their office visit helps to prepare both the patient and you to have the most comprehensive and efficient visit possible.

Filling the gap: Uniting primary and palliative care

Filling the gap: Uniting primary and palliative care

Primary care is…well…primary in delivering coordinated, patient-centered care. But the combination of primary and specialty clinicians along with those in palliative care can deliver another layer of support at a critical time in a patient’s life.

Cost/benefit of direct oral anticoagulants

Cost/benefit of direct oral anticoagulants

More than 5 million people in the U.S. have atrial fibrillation, leading to an increased risk of stroke and related heart problems. Here’s a cost/benefit analysis of some of the leading medication options for treating this prevalent condition and the role of PGx.